Ignyta, Inc. – Cancers With RET Alterations

Access Program Information

Expanded access to RXDX-105 will be given to patients with cancers harboring RET alterations
who have not received TKIs that target RET alterations, who do not qualify for participation
in, or who are otherwise unable to access, an ongoing clinical trial for RXDX-105.